Business · 20/11/2013
FDA Extends Comment Period for Draft Guidance on Early-Phase Clinical Trials of Cellular and Gene Therapy Products
The FDA is extending the comment period for a draft guidance on designing early-phase clinical trials for cellular and gene therapy products, allowing more time for public discussion and comments.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →